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Background: A number of epidemiological studies have established a link between insulin resistance and the
prevalence of depression. The occurrence of depression was found to precede the onset of diabetes and was
hypothesized to be associated with inherited inter-related insufficiency of the peripheral and central insulin
receptors. Recently, dicholine succinate, a sensitizer of the neuronal insulin receptor, was shown to stimulate
insulin-dependent H2O2 production of the mitochondrial respiratory chain leading to an enhancement of insulin
receptor autophosphorylation in neurons. As such, this mechanism can be a novel target for the elevation of
insulin signaling.
Results: Administration of DS (25 mg/kg/day, intraperitoneal) in CD1 mice for 7 days prior to the onset of stress
procedure, diminished manifestations of anhedonia defined in a sucrose test and behavioral despair in the forced
swim test. Treatment with dicholine succinate reduced the anxiety scores of stressed mice in the dark/light box
paradigm, precluded stress-induced decreases of long-term contextual memory in the step-down avoidance test
and hippocampal gene expression of IGF2.
Conclusions: Our data suggest that dicholine succinate has an antidepressant-like effect, which might be mediated
via the up-regulation of hippocampal expression of IGF2, and implicate the neuronal insulin receptor in the
pathogenesis of stress-induced depressive syndrome.
Keywords: Dicholine succinate, Insulin-like receptor, Insulin growth factor 2, Hippocampus, Stress-induced
anhedonia, MouseBackground
Recent epidemiological studies have established a link
between diabetes and the prevalence of depression [1,2].
The presence of depressive symptoms is documented in
12.8–29% of males and 23.8–30.5% of females with
newly diagnosed diabetes [3,4]. A positive relationship
between insulin resistance and the severity of depressive
symptoms has been identified in cross-sectional studies
[5,6]. Depression in patients with diabetes can result* Correspondence: t.strekalova@maastrichtuniversity.nl
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reproduction in any medium, provided the orfrom the chronic psychological and medical conditions
associated with the disease [7,8]; however, the occur-
rence of depression was found to precede the onset of
diabetes which, apart from the behavioral factors and
changes in eating habits often accompanying depression,
might be associated with inherited inter-related insuffi-
ciency of the peripheral and central insulin receptors
[9,10].
The neuronal insulin receptors belong to an insulin re-
ceptor subfamily of receptor tyrosine kinases (Figure 1A)
and many of these receptors have been shown to be
involved in multiple mechanisms of synaptic plasticity as
well as differentiation and cell survival [11-13]. Analysisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Insulin receptor subfamily of receptor tyrosine kinase family. (Only functionally important areas of interaction shown). (A) The
neuronal insulin receptor (INSR), insulin-like growth factor 1 receptor (IGF1R), insulin receptor-related protein (INSRR), and receptors to
neurotrophins NGF (NTRK1), BDNF and NT-4 (NTRK2), and NT-3 (NTRK3) belong to an insulin receptor subfamily of receptor tyrosine kinases
whose members are well documented to regulate cell survival and differentiation and play a role in synaptic plasticity. (B) Analysis with the
UniProt/KB Swiss-Prot data bank reveals high structural homology between the catalytic site sequences of the insulin receptor, insulin-like growth
factor 1 receptor, and NTRK2 (TrkB) receptor. (C) Structure comparison with the UniProt/KB Swiss-Prot data bank suggests high structural
homology of the activation loop sequences of the insulin receptor, insulin-like growth factor 1 receptor, NTRK1, NTRK2 (TrkB), and
NTRK3 receptors.
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high structural homology between the catalytic sites and
the activation loops of the insulin receptor and TrkB
(Figures 1B, C); it is well known that TrkB manifests a
role in the stress response [14-16]. The neuronal insulin
receptor is involved in the control of synaptic functions,
myelination, plasticity and metabolic processes [17-19]
and expresses a robust density in the hippocampus and
cerebral cortex [20,21]. Compromised signaling of insu-
lin receptors can result in cognitive deficits [22,23] and
insulin signaling has been shown to regulate dopamine-
mediated neurotransmission in animal models [24], in-
fluence the function of norepinephrine and serotonin
transporters and consequently extracellular levels of nor-
epinephrine and serotonin [25].
A key regulatory event of neuronal insulin receptor
function, the insulin-stimulated autophosphorylation of
the insulin receptor kinase at tyrosine residues, was
lately found to be dose-dependently activated by dicho-
line salt of succinic acid (dicholine succinate, DS) sug-
gesting the importance of DS in the mitochondrialbiochemical pathway [26-28]. The presence of DS,
and other respiratory substrates, stimulates insulin-
dependent H2O2 production in the mitochondrial
respiratory chain leading to an enhancement of insulin
receptor autophosphorylation in cerebellar neurons
[28,29]. As DS elevates the insulin-stimulated non-basal
autophosphorylation of the insulin receptor it is consid-
ered an important endogenous sensitizer of the neuronal
insulin receptor. Several studies demonstrate the bio-
logical effects of neuronal insulin receptor stimulation,
via the mitochondrial respiratory chain using endogen-
ous and exogenous compounds, and suggest that these
effects are implicated in the stress response and the
pathogenesis of a depressive-like state. For instance,
thiazolidinediones, which act as potent sensitizers of the
neuronal insulin receptor, enhance brain glucose
utilization though increased neuronal mitochondrial bio-
genesis [30], decrease neuronal damage [31] and evoke
anti-inflammatory effects [32-34]. Rosiglitazone, one of
the insulin sensitizers of the thiazolidinedione class, has
been found to induce an antidepressant-like effect in the
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portantly, this drug and another insulin receptor
sensitizer, pioglitazone, were recently reported to be ef-
fective for the treatment of a major depressive disorder
that was refractory to standard antidepressant treatment
and accompanied by insulin resistance [36,37].
Intraperitoneal administration of DS for 7 days at
doses of 10 and 25 mg/kg/day, but not at 1 mg/kg, res-
cued a 30%-decrease of brain N-acetylaspartate/creatine,
a marker of neuronal function and viability, in middle-
aged C57BL/6 N mice. In rats, the same treatment at all
three doses rescued learning in step-through passive
avoidance and a 4-day Morris water maze test; addition-
ally, brain levels of N-acetylaspartate/creatine were also
increased which were compromised in a model of
chronic cerebral hypoperfusion [28]. Similarly, treatment
with the highest dose of DS used in this study, resulted
in a recovery of the acquisition of the step-through pas-
sive avoidance task and choline acetyltransferase activity
which were suppressed in a rat model of beta-amyloid
peptide-(25–35)-induced toxicity.
The current study’s primary objectives were to evalu-
ate the effects of intraperitoneal administration of DS
for 7 days at a dose of 25 mg/kg/day on the development
of depressive syndrome in a mouse chronic stress model
and to relate this state to deficits in the step-down in-
hibitory avoidance learning model [38,39] in addition to
anxiety-like behavior in the dark/light paradigm. A sec-
ondary objective was to investigate the hippocampal
gene expression of insulin-like growth factor two (IGF2),
a member of the receptor tyrosine kinase family, which
is related to insulin signaling and similarly to the effects
of DS on the mechanisms of cholinergic neurotransmis-
sion [40]. In a separate study, we observed that Illumina
analysis pointed to enhanced hippocampal expression of
this gene and related molecules of IGF1/IGF2 signalling
following DS administration in chronically stressed mice
with comparison to vehicle-treated animals (Strekalova
and LePrince, unpublished results; Strekalova and Malin,
in preparation). Importantly, IGF2 was found to interact
with IGF1 and IGF2 receptor types in the brain to in-
duce its biological effects [41]. IGF2 can effectively bind
to the insulin receptor while alternative splicing revealed
a difference in affinity for central and peripheral recep-
tors and elucidated the structural determinants for high-
affinity binding [42-44].
Here, we have used a variant of a recently validated
mouse model of stress-induced anhedonia [45,46]. An-
hedonia, a decreased ability to experience pleasures, is a
core symptom of human depression [47], which in
rodents is regarded to be reflected by a decreased intake
of sucrose or other palatable solutions [48,49] and is re-
versible by antidepressants [5,50,51]. In the paradigm
employed here, anhedonia, which is defined as adecrease below 65% in sucrose preference over water,
occurs in a subgroup of animals. The anhedonic group,
unlike the non-anhedonic group, exhibits increased
floating in the forced swim test and disruptions in nov-
elty exploration, contextual learning in the step-down
inhibitory avoidance test and LTP in the CA1 area of the
hippocampus. Furthermore, the anhedonic group also
displays changes in EEG sleep patterns correlating to
those seen in depressed humans. Chronic treatment with
citalopram and imipramine counteracts the manifest-
ation of stressed induced depressive-like traits in mice
[45,52-54]. In this study, a 10-day stress protocol com-
prises of night time rat exposure and day time applica-
tion of social defeat. Induction time of anhedonia was
considerably shortened by the dual application of stres-
sors, each of which was shown to effectively induce a he-
donic deficit [15,46]. Intraperitoneal administration of
DS at 25 mg/kg/day for 7 days was chosen since the
same treatment was found to induce neurochemical
alterations and beneficial behavioral effects lasting up to
at least two weeks [28]. As a reference, the tricyclic im-
ipramine (7 mg/kg/day) was delivered via drinking water
1 week before the onset of stress and throughout the en-
tire stress procedure in accordance to a previously vali-
dated protocol [53]. Separate studies using the same
model as the current study showed that one-week
pre-treatment with daily intraperitoneal imipramine
injections (15 mg/kg/day) in CD1 mice significantly
attenuated stress-induced changes in the sucrose and
forced swim test as compared with vehicle-injected
animals [53].
Methods
Animals and housing
For the chronic stress experiment, we used male CD1
mice, widely used in behavioral, biochemical and mo-
lecular research. Male mice (age: 3 months) were pur-
chased from Charles River (Sulzfeld, Germany). Ten
days before the behavioral experiments, mice were
housed single-caged under a reverse 12 h : 12 h light–
dark cycle (lights on: 21:00 h) in standard laboratory
conditions (22 ± 1°C, 55% humidity, food and water ad
libitum). All experiments were carried out in accordance
with the European Committees Council Directives
and had been approved by the Animal Experimental
Committee of Claude Bernard University of Lyon
and the Animal Ethical Committee of the University
of Maastricht.
General conditions of experiment
Parameters of social behavior were determined one week
before the chronic stress procedure in a social inter-
action test as described elsewhere [46,53]. Body weight
and baseline preference to a 1% sucrose solution (see
Cline et al. BMC Neuroscience 2012, 13:110 Page 4 of 14
http://www.biomedcentral.com/1471-2202/13/110Sucrose Test) were evaluated as well. The experimental
and control groups were balanced upon these para-
meters [46,53]. Together, 75 mice were assigned to a
stress group and 25 controls constituted a non-stressed
control group. Among animals from a stress group,
twenty five mice received either no treatment, were trea-
ted with imipramine or with DS. Control mice were ei-
ther not treated (n = 8), treated with imipramine (n = 8)
or DS (n = 9). In control and stress groups, imipramine
(7 mg/kg/day) was administrated via drinking water
starting 7 days prior the onset of stress and lasting the
entire duration of the stress procedure (Figure 2).
The current reference antidepressant treatment was
selected because of its maximal effects in lowering the
rate of stress-induced anhedonia over other methods of
delivery and doses of antidepressants [53,55]. Previous
experiments revealed a weaker effect of one-week anti-
depressant pre-treatment with daily i.p. injections of
imipramine (15 mg/kg/day) in CD1 mice for stress-
induced depressive-like changes [53]. DS was admini-
strated during 7 consecutive days preceding chronic
stress. Additionally to baseline measurements, sucrose
consumption tests were performed after 7 and 10 days
of the chronic stress procedure (see Rat exposure while
in a small container, Social defeat stress); animals were
weighed weekly during the study and at the end of the
stress protocol. On day 2 after stress, animals were
tested in the dark/light test; on days 3 and 4, step down
avoidance test was performed. Five days after the ter-
mination of the stress procedure, mice were tested in
the forced swim test (see below) and on the next day
sacrificed for gene expression analysis (see below;
Figure 2).
Chronic stress experiment
The chronic stress procedure lasted 10 days (Figure 2).
Each day, stressors were used in the same sequence: be-
tween 18.00 and 9.00 rat exposure while in a small con-
tainer was applied. 30-min sessions of social defeat wereFigure 2 Timeline of study. Application of stress, drugs and behavioral teemployed twice daily between 11:00 and 16:00. An inter-
session interval between the application of two social de-
feat stress sessions and between social defeat and rat-
exposure procedures was at least 2 h.
Rat exposure while in a small container
Mice were introduced to transparent glass cylindrical
containers (15 cm ×  8 cm) and placed into the
rat cage (15-h exposures were performed between
18.00 - 9.00).
Social defeat stress
Social defeat procedures took place during the dark
phase; to enable a visual control over the resident-
intruder confrontation, the test was carried out under
red light. In a preliminary test, aggressive individuals of
the CD1 mouse strain that were able to attack the
counter-partners in less than 60 s without injuring them
were selected for this procedure similar to commonly
used protocols of social defeat stress [56,57]. These ani-
mals were introduced in the home cages of mice from
the stress group during social defeat sessions, deviating
from originally proposed paradigms of social defeat [58]
but broadly used in a variety of experimental situations
[57,59,60]. Social interaction was set up in the home
cage of stressed animals as it enhances the impact of the
stress procedure in a lasting manner. In a variant pro-
cedure, a defeated animal is left in chronic contact with
the olfactory cues of the aggressive intruder, such that
exposure to a psychological stressor is chronic although
the actual agonistic experience is intermittent. Average
duration of each session was 30 min in accordance with
commonly used protocols [58,60]. During social defeat
stress, test mice typically showed flight response, sub-
missive posture and vocalization. Pairs of animals were
carefully observed in order to exclude any physical harm.
In rare cases of its incidence, aggressive individuals were
immediately removed from the cage of resident mice.
Total duration of social defeat stress was 10 days,sting in the chronic stress study.
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using aggressive CD1 mice [53,55].
Sucrose test
Mice from all groups were simultaneously given for 8 h
(between 9.00 – 17.00 h) a free choice between two bot-
tles, one with 1%-sucrose solution and another with tap
water. To prevent possible effects of side-preference in
drinking behavior, bottle position was switched after 4 h.
No previous food or water deprivation was applied be-
fore the test. To minimize the spillage of liquids during
sucrose test, bottles were filled in advance and kept
inverted for at least 12 h prior to testing in the same
room where testing took place. This method was shown
to ensure a low error of measurement (up to 0.1 ml). To
decrease the variability in sucrose consumption during
the very first exposure to sucrose solution (baseline su-
crose test), 18 h before baseline animals were allowed to
drink a 2.5% sucrose solution in a one-bottle paradigm
for 2 h. The intake of water and sucrose solution was
estimated by weighing the bottles before and after free
access to the liquids. Sucrose preference was calculated
as a percentage of the consumed sucrose solution from
the total amount of liquid drunk:
Sucrose Preference ¼ V Sucrose solutionð Þ=½
V Sucrose solutionð Þ þ V Waterð Þ
 100%
A decrease of sucrose preference to a level below 65%
measured at the 10th day of continuous stress applica-
tion was taken as a criterion for anhedonia. This criter-
ion was based on the fact that none of the control
animals exhibited < 65% preference for sucrose at that
time point of the study. In addition, our previous results
indicated that mice matching this criterion showed a
depressive-like syndrome [53,61].
Forced swim test
Forced swim test was performed five days following ter-
mination of the stress procedure as previously described
[46,53]. We used a large size pool (square pool: 21 cm ×
42 cm × 15 cm) illuminated with red lighting, water
temperature was kept at 30°C and water height was
10 cm. The modified forced swim test employed here
was shown to prevent behavioral artifacts in this test
caused by chronic stress-induced hyperlocomotion. Pre-
vious studies show that, with standard protocols of the
forced swim test [62], chronically stressed mice exhibit
hyperactivity which masks depressive-like behaviors in
most behavioral tests [62]. For instance, chronically
stressed C57BL6N mice show increased swimming be-
havior in brightly illuminated pools that is abolished
with a low dosage of diazepam or testing these animalsunder red light [62]. Mice were introduced 2 min to the
pool for a single swimming session. The latency of the
first episode of floating determined as absence of any
directed movements of the animals heads and bodies
(duration more than 3 sec) and duration of floating were
scored off-line. Visual scoring was validated as described
elsewhere [63] with CleverSys software (CleverSys, VA,
USA).
Dark–light box
The dark/light box consisted of two Plexiglas compart-
ments, one black/dark (15 cm × 20 cm × 25 cm) and
one lit (30 cm × 20 cm × 25 cm) connected by a tunnel.
Mice were placed into the black compartment from
where they could visit the lit box illuminated by a light
intensity of 5 Lux. Our studies showed that with the
classical protocol of the dark–light box, chronically
stressed mice exhibit light-induced hyperlocomotion
that confounds the evaluation of anxiety-related beha-
viors in this paradigm [62]. In chronically stressed
C57BL6N mice, increase in time spent in the lit com-
partment under lighting of 600 Lux is abolished with a
low dosage of diazepam; the same effect as the treatment
can be achieved by dimming down the illumination or
using red light [62]. Latency of the first visit to the lit
box, total duration spent therein and number of visits to
this anxiety-related area were scored by visual observa-
tion over 5 min.
Step-down inhibitory avoidance learning test
Control, stressed non-anhedonic and stressed anhedonic
mice were analyzed for hippocampus-dependent mem-
ory in a step-down inhibitory avoidance paradigm. The
step-down apparatus (Technosmart, Rome, Italy) con-
sisted of a transparent plastic cubicle (25 cm × 25 cm ×
50 cm) with a stainless-steel grid floor (33 rods 2 mm in
diameter) onto which a square wooden platform (7 cm ×
7 cm × 1.5 cm) was placed. A shocker was used to
deliver an alternating electric current (AC, 50 Hz,
Evolocus, Terrytown, NY, USA). In this paradigm, ani-
mals were trained not to step down from a platform
onto a grid floor to avoid an electric shock. During the
training session, mice were placed onto the platform in-
side a transparent cylinder for 30 s to prevent them from
immediately stepping down. After removal of the cylin-
der, the time until the animal left the platform with all
four paws was measured as baseline latency of step
down. Immediately after step down, mice received a sin-
gle electric foot-shock (0.5 mA, 2 sec) and returned to
their home cages. Twenty four hours later, during the re-
call trial session, animals faced the same context as in
the training session. Latency of step down with all four
paws was measured until 180 s elapsed. According to
previously validated criteria for the acquisition of the
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cies measured in animals during a recall session are
taken as a sign of long-term learning.
Administration of compounds in chronic stress study
Imipramine (Sigma-Aldrich, St. Louis, MO, US) was dis-
solved in tap water; the solution was freshly prepared
every 2–3 days. Since imipramine is light sensitive, bottles
were protected by aluminum covers. The calculation of
the concentration of imipramine in drinking water was
based on the previously evaluated mean volume of daily
water consumption in CD1 mice that was about 3.5 ml
and on the dosage of treatment. Dosage for imipramine
was set at 7 mg/kg/day as previous studies showed that
chronic administration of imipramine at15 mg/kg/day
with drinking water, but not 7 mg/kg/day, significantly
affects sucrose intake and locomotor behaviour in naïve
C57BL/6 N mice [55]. Imipramine was delivered with
drinking water starting 1 week before the onset of stress
and then throughout the entire duration of the chronic
stress procedure. DS, provided by Buddha Biopharma Oy
Ltd (Helsinki, Finland), was dissolved in water for
injection and administrated via daily i.p. injections at
25 mg/kg/day for 7 consecutive days; this scheme of treat-
ment was demonstrated to evoke memory-enhancing
effects in mice and rats and neurochemical effects lasting
over a period of two weeks [28]. The volume of DS and
vehicle injections was 0.01 ml/g body weight 0.01 ml/kg.
Brain dissection
Mice were sacrificed by cervical dislocation. The brains
were quickly removed and dissected on ice, dissected
hippocampi material were kept frozen at −80°C.
Real-time PCR assay
Total RNA was isolated from mouse brain using RNeasy
RNA extraction kit with DNaseI treatment following the
manufacturer’s instructions (Qiagen, Hilden, Germany).
Using random primers and Superscript III transcriptase
(Invitrogen, Darmstadt, Germany), 1 μg total RNA was
converted into cDNA. Specific primers for IGF2 gagttca
gagaggccaaacg (forward), ttagtgtgggacgtgatgga (reverse)
were purchased from Sigma-Aldrich (Sigma-Aldrich,
St. Louis, MO, US). The housekeeping gene glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH) was used as
a reference gene for quantification. PCR was performed
with 50 ng cDNA in a 25 μl reaction volume containing a
SYBR Green Master Mix (Roche, Mannheim, Germany).
Amplification was carried out utilizing a Roche LightCy-
cler 480 sequence detection system (Roche). Cycling con-
ditions were 50°C for 2 min, 95°C for 10 min followed by
a 40-cycle amplification at 95°C for 15 s, and 57°C for
1 min. Experiments were repeated two times and samples
were analyzed in triplicate. Results of the real-time PCRdata were represented as Ct values, where Ct is defined as
the threshold cycle of PCR at which amplified product
was first detected. To compare the different RNA samples,
we used the comparative Ct method and compared the
RNA expression in samples to that of the control in each
experiment.
Statistical analysis
Data were analyzed with GraphPad Prism version 5.00
for Windows (San Diego, CA, USA) using two-way
ANOVA followed by Bonferroni post-tests; where appro-
priate, one-way ANOVA with Tukey's Multiple Com-
parison Test was utilized while Fisher’s exact test was
used to compare group size. The level of confidence was
set at 95% (p < 0.05) and data are shown as mean± SEM
unless otherwise stated.
Results
Assessment of anhedonia induction
Initially, mice assigned to distinct experimental groups
had a similar sucrose preference (Figure 3A), intake of
sucrose solution and water, as well as body weight (data
not shown). Two-way ANOVA revealed a significant dif-
ference between stress and control groups (F= 11.9,
DFn= 1; DFd= 12, p =0.0058) while Bonferroni’s indi-
cated that the non-treated stressed group had a signifi-
cant decrease in sucrose preference (p < 0.05) unlike the
imipramine and dicholine succinate treated groups
which were not significant; indicating the ability of DS,
like imipramine, to prevent a reduction in sucrose pre-
ference for the stressed cohort (Figure 3B). During the
chronic stress study, sucrose preference was assessed at
day 7 and 10 (end of stress, Figure 3C, D E) affirming
that only the non-treated stress group showed a significant
decrease in sucrose consumption (F=12.75, DFn=1,
DFd= 87, p=0.0006) and at day 10 the mean for the non-
treated stress group (mean=64.06) dropped below the
defined threshold for anhedonia (sucrose preference below
65%). Neither the imipramine nor the DS treated stressed
groups showed a significant change in sucrose preference
at either day (F=1.686, DFn=1, DFd =89, p=0.1975 and
F= 2.252, DFn=1, DFd=90, p=0.1369, respectively)
reiterating the ability of both DS and imipramine to pre-
vent a decrease in sucrose preference for the stressed
animals.
Previous studies have evidenced the significance of ab-
solute sucrose intake as a parameter sensitive to the
effects of antidepressants in chronic stress paradigms
[53,64]. A counteraction of stress-induced decrease in
absolute sucrose intake is taken as a sign of
antidepressant-like effects of the treatment [48]. Follow-
ing the stress procedure, absolute sucrose intake
was measured (Figure 3F) and two-way ANOVA with
Bonferroni’s post-test attested that only non-treated
Figure 3 Imipramine and dicholine succinate counteract stress-induced decrease in sucrose preference and sucrose intake. (A) Groups
of mice assigned for planned treatment had similar means of sucrose preference before the beginning of dosing. (B) Two-way ANOVA revealed a
significant effect for the stress condition in sucrose preference F= 11.9, DFn= 1, DFd= 12, p =0.0058 * vs respected control. (C) NoT stress mice
showed a significant reduction for sucrose preference at days 7 and 10 in relation to the stress condition F= 12.75, DFn= 1, DFd= 87, p =0.0006,
Bonferroni day 7, p< 0.05 * respected control; day 10, p< 0.01 ** vs control. (D,E) Imi and DS stress mice did not show significant differences
neither at day 7 nor day 10 for the stress condition F= 1.686, DFn= 1, DFd= 89, p=0.1975 and F= 2.252, DFn= 1, DFd= 90, p= 0.1369 respectively.
(F) Following chronic stress, the total sucrose intake was measured and two-way ANOVA revealed an overall condition effect while Bonferroni
showed a significant reduction in sucrose intake only in the NoT stress group F= 5.352, DFn= 1, DFd= 88, p= 0.0230, Bonferroni: NoT p< 0.05, DS,
Imi p> 0.05 * vs respected control. NoT: non-treated group; Imi: imipramine-treated group, DS: DS-treated group. Data is shown as mean± SEM.
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(F = 5.352, DFn = 1; DFd = 88, p = 0.0230, Bonferroni:
NoT p < 0.05, DS, Imi p > 0.05) The total number of an-
hedonic mice observed among the imipramine-treated
(n = 6) and DS-treated (n = 8) stressed groups was lower
than in the non-treated stressed group (n = 14, p = 0.02
and p = 0.08, respectively, Fisher’s exact test) further sug-
gesting that both compounds counteract a development
of stress-induced anhedonia.
Effects of treatment on floating behavior
Latency to floating was significantly altered by treatment
in the forced swim test as revealed by two-way ANOVA(F= 4.652, DFn= 2, DFd= 89, p= 0.0120); however,
Bonferroni’s post-test did not detect any differences be-
tween stressed and control groups suggesting that non-
treated animals were significantly faster to quit swim-
ming compared with treated animals. As with latency to
floating, the duration of floating was significantly diver-
gent between control and stress cohorts but no differ-
ences were seen between groups (F= 5.333, DFn = 1,
DFd= 89, p= 0.0232, Figure 4A). The effect of treatment
was robust albeit not significant (p =0.0590) indicating
that the stressed condition had a significant effect on float-
ing duration while non-treated animals had a very strong
tendency for increased periods of floating suggesting
Figure 4 Dicholine succinate reduces stress-induced floating and anxiety-like behaviors, but not a decrease of body weight. (A) Latency
of floating had an overall significant difference for treatment while the duration of floating had an overall significant difference for the stress
condition F= 4.652, DFn= 2, DFd= 89, p= 0.0120 and F= 5.333, DFn= 1, DFd= 89, p= 0.0232 respectively two-way ANOVA; * vs non-treated, # vs
respected controls. (B) ANOVA revealed a significant difference for time spent in the lit compartment with Tukey showing only a difference
between the Not and DS treated stress groups F= 4.469, DFn= 3, DFd= 39, p= 0.0086, Tukey p<0.01 ;*vs respected control. No significant
difference in latency of exit was observed. (C) Two-way ANOVA revealed a significant difference in body weight for the stress condition in all
groups F= 66.81, DFn= 1, DFd= 89, p< 0.0001. * vs respected controls NoT: non-treated group; Imi: imipramine-treated group, DS: DS-treated
group. All data is shown as mean± SEM.
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antidepressant-like effect.Evaluation of anxiety scores
The level of anxiety was significantly altered between
groups as revealed by total duration spent in the lit com-
partment (one-way ANOVA, F=4.469, DFn=3, DFd=39,
p= 0.0086, Figure 4B) Tukey’s post-test showed that the
non-treated stress group spent a very significantly dimin-
ished duration (p< 0.01) in the lit compartment compared
with the DS treated stress group; no significant differences
were revealed amidst the other groups indicating the abil-
ity of DS to block stress-induced anxiety. Latency to exit
was not different between any of the groups (one-way
ANOVA, F= 1.232, DFn=3, DFd=41, p= 0.3103).Changes in body weight
After the termination of stress, body weight was signifi-
cantly shifted between control and stress animals and all
stress groups showed an extremely significant decrease
in body weight compared with controls (two-way
ANOVA, F= 66.81, DFn= 1, DFd= 89, p <0.0001,
Bonferroni, NoT, Imi, DS p < 0.001, Figure 4C).
Step-down avoidance learning
All stress groups tested showed a significant difference
on test day as compared to the baseline day (one-way
ANOVA, F= 23.27, DFn= 7, DFd= 192, p < 0.0001,
Figure 5A) suggesting that all groups were able to ac-
quire the task while no observed difference in baseline
shows that initial anxiety levels were the same between
groups. Tukey’s post-test revealed that non-treated stress
Figure 5 Effect of imipramine and dicholine succinate on step-down avoidance learning and hippocampal expression of IGF2. (A) All
groups showed a significant increase in the latency to step down as compared to their respective baselines one-way ANOVA F= 23.27, DFn= 7,
DFd= 192, p< 0.0001 *** vs baseline while the NoT group was significantly lower for the recall test compared to control indicating a disruption in
contextual learning # vs control. (B) There was an overall significant difference seen in the hippocampal gene expression for IGF2, while Tukey’s
post-test revealed differences for IGF2 gene expression between DS and Imi treated groups and DS and NoT treated groups p < 0.01, F= 6.232,
DFn= 3, DFd= 33, p= 0.0018. # vs NoT & vs Imi; NoT: non-treated group; Imi: imipramine-treated group, DS: DS-treated group. All data is shown as
mean± SEM.
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in the 24 hr recall showing reduced latencies to step
down (p < 0.05) whilst imipramine and DS treated stress
animals did not show any difference, thus suggesting
stress disrupted learning in non-treated animals and
demonstrating the ability of DS and imipramine to pre-
serve contextual memory for stressed animals.Hippocampal gene expression of insulin-like
growth factor 2
IGF2 expression levels were measured following the
stress procedure. Hippocampal expression levels of IGF2
were significantly altered in stressed animals (one-
way ANOVA, F= 6.232, DFn= 3, DFd= 33, p= 0.0018
Figure 5B). Post-test with Tukey revealed that DS treated
animals had a significant increase in IGF2 expression
levels compared with non-treated and imipraminetreated groups (p < 0.01) while no significant differences
were observed between other groups.
Altogether, pre-stress treatment with imipramine and
DS prevented a stress-induced decrease of sucrose in-
take and preference, counteracted a stress-induced in-
crease in floating, conserved contextual inhibitory
learning and averted anxiety-like behavior; however, the
applied drugs did not prevent a loss in body weight. A
pronounced up-regulation of IGF2 gene expression in
the hippocampus accompanied these behavioral effects
of DS treatment in chronically stressed mice.
Discussion
Initial values of sucrose test parameters were similar be-
tween all groups (Figure 3A) and stress exposure low-
ered sucrose preference in agreement with other reports
[49,61,65]. Stressed mice treated with DS showed no sig-
nificant change in sucrose preference measured on the
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(Figure 3E). Administration of the classical antidepres-
sant imipramine resulted in a similar effect. Earlier, we
have shown in a model of stress-induced anhedonia
that the stress-induced decrease in sucrose preference is
paralleled by a reduction in sucrose intake [46,53]. In
particular, a disruption of synaptic plasticity and pro-
nounced behavioral despair in the forced swim test were
observed in mice, which showed a decrease in both su-
crose intake and preference but not a reduced sucrose
preference alone, which occurs exclusively at the ex-
pense of high water intake [45,51,53]. Thus, the partial
preclusion of the stress-induced reduction for both su-
crose preference and consumption by treatment with
imipramine and DS manifests their antidepressant-like
activity in our study. Importantly, administration of im-
ipramine and DS did not alter sucrose test parameters in
control animals ruling out any possible confounding
artifacts for sucrose test measurements which could be
related to treatment. Imipramine, used as a reference
drug in this experiment, is well documented to counter-
act the stress-induced decrease in sucrose intake and
preference seen in rodents [51,65]. Overall, our data sug-
gest that chronic administration of imipramine and DS
has the potential to counteract the development of
stress-induced anhedonia, i.e. elicits an antidepressant-
like activity in the mouse paradigm employed in the
present study.
Described above evidences, for antidepressant-like
effects of DS in the sucrose test, are in line with the out-
come from the forced swim test. While the effects of
chronic stress on the latency to the first episode of float-
ing were not significant, DS and imipramine treated
mice had significantly higher values of this parameter
(Figure 4A). DS administration strongly reduced the dur-
ation of floating in the chronic stress experiment sug-
gesting that treatment with DS prevents a stress-induced
state of behavioral despair as measured by elevated float-
ing behavior (Figure 4A) [45,46,48,66]. In the current
work, these antidepressant like effects observed with DS
administration were also demonstrated for treatment
with imipramine; earlier, we reported congruent changes
in the forced swim test following chronic administration
of citalopram [53]. Coinciding with these results, an-
other insulin sensitizer, rosiglitazone, was reported to re-
duce immobilization and floating behaviors in mouse tail
suspension and forced swim tests respectively [35].
Both treatment with imipramine and DS decreased
anxiety scores as shown by increased time spent in the
lit compartment in the dark/light box indicating their
anxiolytic and anti-stress effects (Figure 4B). Such effects
are well documented for imipramine and other tricyclics
[48]. Elevated anxiety was found to parallel anhedonia
induction in chronic stress models [15,45,48,49].In the present study, the stress-induced loss in body
weight does not correlate with an occurrence of anhedo-
nia and depressive-like syndrome in mice. However, it
has been shown that antidepressant effects of pharmaco-
logical treatment parallel a restoration of body weight
[48,67]. We did not find such an effect with imipramine
and DS treatment (Figure 4C) in the present study but it
must be noted that a lack of positive effects on the res-
toration of body mass in depressed patients is well docu-
mented for many antidepressants including fluoxetine
and other SSRIs [48,66].
Treatment with imipramine and DS prevented stress-
induced memory impairment in the step-down inhibi-
tory avoidance task (Figure 5A). The latency of step
down measured twenty four hours after training session
was previously validated as a reliable measure of
hippocampus-dependent performance in mice [38,39].
Deficits in hippocampus-dependent performance were
earlier shown to be a specific feature of stressed anhe-
donic mice as compared to stressed individuals without
a depressive syndrome in various chronic stress para-
digms. Treatment with citalopram was shown to rescue
contextual fear conditioning in a model of stress-
induced anhedonia [38,45,53]. Since imipramine admin-
istration also precluded deficits in the step-down avoid-
ance test, beneficial effects of DS on learning can be
accounted for by its antidepressant action which is gen-
erally accompanied by an improvement in cognitive
function in clinical and pre-clinical studies. These data
are in line with ameliorative effects of DS on
hippocampus- and cortex-dependent learning in step-
though and Morris water maze paradigms which this
drug exerted under pathological conditions of diverse
origins [28,29].
Our study evidenced a sharp increase in hippocampal
gene expression of IGF2, a member of the insulin gene
family with known neurotrophic properties, after admin-
istration of DS, but not imipramine, in stressed mice
(Figure 5B). Utilizing the hippocampi of mice from the
same experimental groups (five animals per each group
were analyzed), gene expression profiling was performed
using Illumina technology (Integragen, Evry, France and
Northwestern Chicago University, USA). This study
revealed significant effects of DS on the expression of a
number of functionally important genes (Strekalova and
Malin, in preparation). Therefore, total RNA was iso-
lated using RNeasy Mini Kit (Qiagen, Hilden, Germany).
Total RNA samples were hybridized to IlluminaBead-
Chips (MouseRef-8 v2 Expression BeadChip; Illumina,
Inc. San Diego, CA, USA) which were prepared using
the IlluminaTotalPrep RNA Amplification kit (Applied
Biosystems/Ambion, Carlsbad, CA, USA); the samples
were assigned to the chips in random order with the
constraint that no two samples from the same group
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experimental groups with the chips. Microarray data
were analyzed using standard analysis procedures which
included assessment of the overall quality of array data
and statistical evaluation of differentially expressed genes
(Integragen, Evry, France). Once the quality of array data
was confirmed, the Gene Chip Operating System
(Illumina, Inc. San Diego, CA, USA) was used to calcu-
late signal intensities, detection calls, and their asso-
ciated P values for each transcript on the array. Gene
expression was normalized to the expression of the
house gene beta-actin, due to its stable expression, and
calculated as percent mean of the control group. Differ-
ences in gene expression between groups were evaluated
using ANOVA followed by Fisher’s Least Significant Dif-
ference test.
In line with the outcome from mRNA evaluation
(Figure 5B), these data revealed a significant increase of
IGF2 expression in stressed DS-treated mice (163.1±30.17%
from control) and its significant decrease in stressed
mice that were not treated (83.0±4.49% from control).
This study indicated that stressed DS-treated mice
showed a significant expression enhancement of Htra1,
HtrA serine peptidase 1 which cleaves IGF-binding pro-
teins (IGFBPs) from IGF1 and IGF2 and activates these
factors, in comparison to non-treated mice (144.3±9.16
vs. 119.2±17.6% from control, respectively). Preliminary
data showed no such changes of IGF2 in the non-
stressed control group. Also, this experiment revealed
significant effects of DS on the expression of other ele-
ments of the IGF1/IGF2 system in chronically stressed
mice, including Htra1, as well as IGF1 and IGF1 recep-
tor, the insulin receptor and several insulin-like growth
factor binding proteins. Again, no such changes were
detected in non-stressed mice treated with DS. While it
is important to study above-mentioned findings with
additional methods, they generally support our data on
elevated mRNA of IGF2 in the hippocampus of DS-
treated stressed mice and suggest this elevation to be a
part of systemic changes in IGF1/IGF2 signaling in these
animals. A lack of such molecular effects in naïve mice
treated with DS might be due to distinct functional
states of the IGF1/IGF2 system during stress and resting
conditions; whereas, the activation of this signaling
might occur as an adaptive mechanism in response to
biological challenges.
A comparison of pharmacologically naïve anhedonic
versus resilient animals in changes of the above-
mentioned elements of IGF1/IGF2 signaling speaks in
favor of the latter view. Our studies revealed an intri-
guing difference in the IGF2 expression between non-
treated stressed anhedonic and resilient animals
(58.8 ± 2.32% vs. 107.2 ± 8.7% from control, respectively),
suggesting the elevated IGF2 to be a correlate of stressresilience while its decrease as a parallel of susceptibility
to a depressive-like state. Moreover, the expression of
Htra1 was reduced in non-treated anhedonic and essen-
tially increased in the resilient group (91.08 ± 6.16% vs.
148.34 ± 11.16% from control, respectively). Anhedonic
and non-anhedonic groups had differential expressions
in most of the other above-listed elements of the IGF1/
IGF2 signaling system (Strekalova and Malin, in prepar-
ation). Thus, the outcome from the gene expression pro-
filing experiment is in line with a suggestion that
enhanced expression of IGF2 can mediate resilience to
stress-induced anhedonia induced by administration of
DS in our study.
IGF2 is widely expressed throughout the brain and is
abundant in the hippocampus [68]. Various challenges
such as acute hypoxia, exposure to toxicity stress and
cerebral ischemia were shown to induce long-lasting
changes in IGF2 expression which is considered to have
an important neuroprotective function [69-71]. IGF2
was recently shown to be an important regulator of
hipppocampal neurogenesis in the context of extinction
in fear conditioning learning [72]. Moreover, IGF2 was
shown to enhance adult neurogenesis [73]. Our results
evidenced suppressive effects of stress on hippocampal
levels of IGF2 demonstrating that chronic stress in mice
has a tendency to decrease the content of this neuro-
trophic factor that might be associated with its above-
mentioned role in the regulation of neurogenesis which
is inhibited by stress [74]. In order to immediately ad-
dress how crucial the role of IGF2 in the development of
stress-induced depressive syndrome might be, a chronic
intrahippocampal administration of this molecule could
be applied with our model. Treatment with DS signifi-
cantly elevated levels of IGF2 in stressed mice above that
of controls. The mechanisms of this effect can be due to
an earlier demonstrated DS-induced enhancement of
choline content and acetylcholine function in the brain
[28] since a functional link between this neurotransmit-
ter system and IGF2 is particularly evidenced by
increased expression of this neurotrophic factor after
choline administration in the hippocampus and frontal
cortex [40,75,76]. In these studies, choline supplementa-
tion increased levels of IGF2 in the hippocampus and
changed expression of its receptors in the septum, it also
enhanced IGF2-induced acetylcholine release and cho-
linergic neurontransmission [40]. Importantly, there was
an increase of choline acetyltransferase activity after DS
treatment in rats subjected to a toxic treatment with
beta-amyloid peptide-(25–35) [28] and elevated IGF2
content in our study on mice were observed two weeks
after the termination of a chronic DS administration
(Figure 2).
Interestingly, recent results evidenced a critical role of
IGF2 in inhibitory avoidance learning as shown in the
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ally explain the beneficial effects of DS on performance
in chronically stressed mice in the step-down inhibitory
avoidance task (Figure 5A). Taking these data into ac-
count and given the fact that hippocampal IGF2 signal-
ing regulates adult neurogenesis in the context of fear
extinction learning [73] it would be of high interest to
assess the expression of IGF2 in the step-down avoid-
ance inhibitory task that is similar to the fear condition-
ing paradigm form of contextual learning. However, the
fact that imipramine did not evoke any effect on IGF2
gene expression while exhibiting both prominent anti-
depressant and memory-enhancing effects similar to DS
suggest that elevated expression of this molecule cannot
be the sole mechanism of antidepressant and memory-
enhancing effects observed for DS in the current study.
Conclusions
Together, our data suggest that the chronic administra-
tion of DS in mice before the onset of stress exerts anti-
depressant-, anxiolytic-like and memory-preserving
effects in a mouse chronic stress depression model simi-
lar to the classical antidepressant imipramine. The
effects of DS parallel a lasting increase of hippocampal
expression of IGF2 that is not observed in imipramine-
treated mice suggesting distinct mechanisms of benefi-
cial action of the two drugs used here in this model of
experimental depression. The latest clinical study
showed the efficacy of insulin receptor sensitizers in
patients who were refractory to a standard antidepres-
sant treatment; thus, arguing for a relevance of hetero-
geneity in neurochemical factors underlying this
disorder and its cure [36,37].
To date, one can only speculate about the specific
mechanisms of the reported effects of DS here. One can
hypothesize that they are mediated by neurotrophins like
IGF2 that activate neurogenesis and evoke anti-
inflammatory effects [74,78,79] as well as associated with
IGF2-induced changes in expression of GluR1 [77],
GABA release and receptor expression [75,80] and activ-
ity of PKC- and calmodulin kinase I-dependent pathways
[75,81]. Additionally, preliminary data suggest anti-
inflammatory effects of DS and other insulin receptor
sensitizers which were used in clinical [32,34,37] and
pre-clinical studies [82]; this can per se, underlie an anti-
depressant effect taking into account emerging evidence
for the role of inflammatory mechanisms in depression
[83,84].
Meanwhile, alterations in insulin signaling pathways
by DS may also represent an important part of the
underlying antidepressant action. A recently found anti-
depressant effect of the neuronal sensitizer thiazolidine-
dione was correlated with a reduction of insulin
resistance [36] and data with pioglitazone also suggestsuch a relationship [37]. Although a link between DS
treatment and insulin sensitivity remains to be deter-
mined in the paradigm applied here, the present study
argues for the potential of agents which like DS, increase
insulin signaling and thereby generating a sustainable
antidepressant-like effect at least as powerful as that of
tricyclics.
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